Digital Australia, AI, and Autolomous pharmaphorum spoke with Alexander Seyf, CEO of Autolomous, about the future of AI in Australian biotech.
Market Access Approval designed from day one: Building global-ready regula... The global pharmaceutical landscape is increasingly defined by the necessity for clinical acceleration without compromising data integrity.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.